Basit öğe kaydını göster

dc.contributor.authorGezer, Uğur
dc.contributor.authorKeskin, Metin
dc.contributor.authorHoldenrieder, Stefan
dc.contributor.authorYoruker, Ebru E.
dc.contributor.authorOzgur, Emre
dc.contributor.authorDalay, Nejat
dc.date.accessioned2021-03-05T16:40:54Z
dc.date.available2021-03-05T16:40:54Z
dc.date.issued2015
dc.identifier.citationYoruker E. E. , Ozgur E., Keskin M., Dalay N., Holdenrieder S., Gezer U., "Assessment of circulating serum DNA integrity in colorectal cancer patients.", Anticancer research, cilt.35, ss.2435-40, 2015
dc.identifier.issn0250-7005
dc.identifier.othervv_1032021
dc.identifier.otherav_c1cbdff8-0c9f-41ae-847c-b93c35d0451d
dc.identifier.urihttp://hdl.handle.net/20.500.12627/128635
dc.description.abstractBackground/Aim: Studies evaluating the integrity of cell-fee DNA (cfDNA) in colorectal cancer (CRC) have led to inconsistent results. Herein, we analyzed the utility of two different DNA integrity indexes (ACTB(384)/ACTB(106) and ALU(247)/ALU(115)) to assess cfDNA fragmentation in Turkish CRC patients. The correlation of circulating nucleosomes (cNUC) with the fragment sizes was also evaluated. Materials and Methods: Seventy two CRC patients and 42 CRC-free control individuals were enrolled in the study. cfDNA was analyzed by quantitative polymerase chain reaction (qPCR). Results: While with ALU(247)/ALU(115) there was a small difference between the groups, an approximately 3-fold (median values=0.12 and 0.34) lower integrity was found in the patients using the ACTB(384)/ACTB(106) ratio (p=0.06). The correlation between cNUC and qPCR threshold cycles was much higher for shorter fragments. Conclusion: Lower DNA integrity and the predominance of mononuclesomes in serum reveal high fragmentation of cfDNA in CRC patients.
dc.language.isoeng
dc.subjectOnkoloji
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleAssessment of circulating serum DNA integrity in colorectal cancer patients.
dc.typeMakale
dc.relation.journalAnticancer research
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume35
dc.identifier.issue4
dc.identifier.startpage2435
dc.identifier.endpage40
dc.contributor.firstauthorID63833


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster